LAG-3, page-3

AIPAC - "Spotlight poster". Sat 12 December 7.15am AEST (Ahjay - have a sleep-in before daily report!!).

PD14-08 Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients.

Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Wagemans J, Vuylsteke P, Jacquin J-P, Brain E, Kümmel S, Pápai Z, Perjesi L, Mueller C, Brignone C, Triebel F.

Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, Belgium;
The Christie NHS Foundation Trust, Manchester, United Kingdom; AZ Sint-Jan Burgge-Oostende AV, Ruddershove, Belgium;
Institut Claudius Regaud, Toulouse, France; GZA ziekenhuizen campus Sint-Augustinus, Oosterveldlaan, Belgium;
Nottingham Cancer Clinical Trials Team (NCCTT), Nottingham, United Kingdom;
National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany;
University Medical Center Groningen, Groningen, Netherlands;
Universitätsfrauenklinik Ulm, Ulm, Germany; AZ Sint-Maarten, Mechelen, Belgium;
CHU UCL Namur, St Elisabeth, Belgium;
Institut de Cancérologie de la Loire (ICO) Lucien Neuwirth, Saint Priest en Jarez, France;
Institut Curie - Hôpital René Huguenin, Saint-Cloud, France;
KEM | Evang. Kliniken Essen-Mitte, Essen, Germany;
MH Egészségügyi Központ Onkológiai Osztály, Budapest, Hungary;
Immutep, Budapest, Hungary; Clinical Development,
Immutep, Berlin, Germany; Research & Development, Immutep, Paris, France.